{"url_path":"/sec/lfcr/8-k/2026-03-16/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-03-16","source_url":"https://www.sec.gov/Archives/edgar/data/1005286/0001005286-26-000007-index.html","accession_number":"0001005286-26-000007","cik":"0001005286","ticker":"LFCR","issuer_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","edgar_url":"https://www.sec.gov/Archives/edgar/data/1005286/0001005286-26-000007-index.html","primary_entity_key":"0001005286","primary_entity_name":"LIFECORE BIOMEDICAL, INC. \\DE\\"},"word_count":142,"has_tables":true,"body_markdown":"Item 2.02    Results of Operations and Financial Condition.\n\nOn March 16, 2026, Lifecore Biomedical, Inc. (the “Company”) issued a press release announcing its consolidated financial results for the fourth quarter and transition period ended December 31, 2025. The press release is furnished herewith as Exhibit 99.1.\n\nThe information in this Item 2.02 of this Current Report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. The information in this Item 2.02 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."}